Accelerated Corneal Cross-linking With Different Riboflavin Solutions

Medical University of Vienna60 enrolled

Overview

Following the Bunsen-Roscoe law, accelerated cross-linking protocols with higher irradiation intensities and shorter irradiation times have been introduced. In addition, new riboflavin solutions with HPMC (hydroxylpropyl methylcellulose) instead of dextran found its way into CXL-treatment. The aim of this trial is to evaluate clinical outcomes in an accelerated corneal collagen cross-linking protocol with different riboflavin solutions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Keratoconus

Interventions

RiboflavinDRUG

Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Progressive Keratoconus * Indication for treatment * Preoperative Pachymetry \> 400 Exclusion Criteria: * Pregnancy * Re-CXL * Keratitis * Other visual acuity limiting eye diseases than corneal ectatic diseases

Locations (1)

Medical University of Vienna, Department of Ophthalmology

Vienna, Austria

Outcomes

Primary Outcomes

Kmax

Steepest Keratometry

Time frame: 12 months

Secondary Outcomes

Postoperative central stromal depth of the Demarcation Line

The depth of the Demarcation Line after CXL will be measured one month postoperatively with an AS-OCT

Time frame: 1 month

LogMAR

Visual Acuity

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.